Clinical Trial Update: Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial comparing SANGUINATE to hydroxyurea in patients with sickle cell disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• SANGUINATE

Snippet

Sponsor: Prolong Pharmaceuticals | Conditions: Sickle Cell Disease | Phase 1 | Status: COMPLETED